Similar articles

• Using hepatitis A and B vaccination as a paradigm for effective HIV vaccine delivery.

  Rhodes SD, Yee LJ. Rhodes SD, et al. Sex Health. 2007 Jun;4(2):121-7. doi: 10.1071/sh06069. Sex Health. 2007. PMID: 17524290
• Local understanding of an HIV vaccine and its relationship with HIV-related stigma in the Dominican Republic.

  Barrington C, Moreno L, Kerrigan D. Barrington C, et al. AIDS Care. 2007 Aug;19(7):871-7. doi: 10.1080/09540120701203295. AIDS Care. 2007. PMID: 17712690
• Clinical considerations in vaccine trials with special reference to candidate HIV vaccines.

  Fast PE, Sawyer LA, Wescott SL. Fast PE, et al. Pharm Biotechnol. 1995;6:97-134. doi: 10.1007/978-1-4615-1823-5_5. Pharm Biotechnol. 1995. PMID: 7551256 Review. No abstract available.
• Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.

  Jackson DJ, Martin HL Jr, Bwayo JJ, Nyange PM, Rakwar JP, Kashonga F, Mandaliya K, Ndinya-Achola JO, Kreiss JK. Jackson DJ, et al. AIDS. 1995 Nov;9(11):1279-83. doi: 10.1097/00002030-199511000-00010. AIDS. 1995. PMID: 8561982 Clinical Trial.
• Factors associated with awareness of and willingness to use PrEP among stable, heterosexual HIV-serodifferent couples in seven African countries, 2019-2022.

  Sharpe JD, Laws RL, West CA, Djomand G, Omolo J, Ramaabya D, Li M, Dlamini S, Motebang M, Marake N, Singano V, Ozituosauka W, McCabe C, Sathane I, Kancheya N, Chisenga T, Malaba R, Ncube G, Philip NM, Biraro S, Charurat ME, Rolle I, Voetsch AC. Sharpe JD, et al. J Int AIDS Soc. 2025 Jun;28(6):e26446. doi: 10.1002/jia2.26446. J Int AIDS Soc. 2025. PMID: 40534141 Free PMC article.